Pro Research: Wall Street peers into Neurocrine Biosciences' prospects

investing.com:

Explore Wall Street's expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy with ProPicks, our newest product featuring strategies that have outperformed the S&P 500 by up to 700%. This New Year, enjoy up to 50% off on a subscription to InvestingPro. In addition, take an extra 10% off a 2-year InvestingPro+ subscription with the code SFY24 or claim an extra 10% off a 1-year InvestingPro+ subscription with the code SFY241 . To ensure ongoing access to valuable content like this, step up your investment game with InvestingPro.

Neurocrine (NASDAQ:NBIX) Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company specializing in neurology and endocrinology, has been navigating a complex landscape of triumphs and setbacks, as reflected in recent analyst reports. With a focus on its flagship product Ingrezza, used to treat Tardive Dyskinesia, and the potential blockbuster crinecerfont for Congenital Adrenal Hyperplasia (CAH), Neurocrine's market performance and strategic decisions have been under close scrutiny.

Ingrezza, the main revenue driver for Neurocrine, has demonstrated strong sales and is projected to maintain a growth trajectory, with peak sales expected to reach $2.9 billion by 2029. Despite the positive outlook, the Inflation Reduction Act (IRA) implementation could impact growth. Analysts have highlighted the importance of label expansions into indications such as cerebral palsy and schizophrenia, although these ventures carry their own risks.

The recent success of crinecerfont in phase III trials has been a beacon of hope, setting up a likely approval and launch towards the end of 2024, targeting a significant